Itch stimuli are detected by specialized primary afferents that convey the signal to the spinal cord, but how itch transmission is regulated is still not completely known. Here, we investigated the roles of the neuropeptide Y (NPY)/Y 2 receptor system on scratch behavior. The inhibitory Y 2 receptor is expressed on mouse primary afferents, and intrathecal administration of the Y 2 agonist peptide YY (PYY) 3-36 reduced scratch episode frequency and duration induced by compound 48/80, an effect that could be reversed by intrathecal preadministration of the Y 2 antagonist BIIE0246. Also, scratch episode duration induced by histamine could be reduced by PYY . In contrast, scratch behavior induced by a-methyl-5HT, protease-activated receptor-2-activating peptide SLIGRL, chloroquine, topical dust mite extract, or mechanical itch induced by von Frey filaments was unaffected by stimulation of Y 2 . Primary afferent neurons expressing the Npy2r gene were found to coexpress itch-associated markers such as natriuretic peptide precursor b, oncostatin M receptor, and interleukin (IL) 31 receptor A. Accordingly, intrathecal PYY 3-36 reduced the scratch behavior induced by IL-31. Our findings imply that the NPY/Y 2 system reduces histaminergic and IL-31-associated itch through presynaptic inhibition of a subpopulation of itch-associated primary afferents.
Introduction
More than 350 years ago itch was defined as an "unpleasant sensation that elicits the desire or reflex to scratch" by the German physician Samuel Hafenreffer (Ikoma et al., 2006) . Although acute itch serves a purpose by initiating scratching that will remove irritants that can cause harm, persistent itch severely affects the quality of life. Itch-inducing, or pruritogenic, substances are detected by specific receptors expressed by primary afferent neurons (Schmelz et al., 1997; Liu et al., 2009) . Neurotransmitters such as natriuretic polypeptide b (Nppb) transmit the signal further to the dorsal horn of the spinal cord (Mishra and Hoon 2013) , where the gastrinreleasing peptide receptor (Grpr) system is subsequently activated (Sun et al., 2009; Aresh et al., 2017) , relaying the signal further to projection neurons that convey the information to the brain (Mu et al., 2017) .
The neurotransmitter neuropeptide Y (NPY) is expressed by spinal GABAergic interneurons located in laminae I-IV of the dorsal horn (Rowan et al., 1993; Bourane et al., 2015) . Under normal conditions, expression of Npy mRNA is below the detection limit in dorsal root ganglia neurons (Usoskin et al., 2015) but becomes significantly upregulated after peripheral nerve injury (Wakisaka et al., 1991) . Spinal NPY interneurons are activated by nociceptive input (Liu et al., 2010; Polgar et al., 2013) and NPY binds to the NPY receptor family, whose Y 1 receptor is expressed on excitatory somatostatinexpressing interneurons in the spinal cord and in a few primary afferent neurons (Zhang et al., 1999) . Activation of the Y 1 receptor results in reduced histaminergic and mechanical itch transmission (Gao et al., 2018) , and conversely ablation or silencing of NPY interneurons results in increased itch and alloknesis upon mechanical stimuli (Bourane et al., 2015) , indicating that the NPY/Y 1 system regulates both mechanical and histaminergic itch.
In the spinal neuronal network, the Y 2 receptor is found in central terminals of primary afferent neurons (Brumovsky et al., 2005; Usoskin et al., 2015; Li et al., 2016; Zeisel et al., 2018) and dorsal rhizotomy completely abolishes Y 2 immunoreactivity in the spinal cord (Brumovsky et al., 2005) ; however, a recent analysis has also shown weak Npy2r mRNA expression in some excitatory (Glut10, Glut11) and inhibitory (Gaba7, Gaba10, Gaba11) neuronal subtypes of dorsal horn interneurons (Häring et al., 2018) . Activation of Y 2 has been shown to have a protective role against the development and maintenance of peripheral neuropathic pain (Solway et al., 2011) . However, the role of the Y 2 receptor in itch is unknown. Y 2 couples via the inhibitory G protein subunits a I and a o (http:// www.guidetopharmacology.org/GRAC/ObjectDisplayForward? objectId5306) and activation of the receptor decreases the firing frequency by activating G-protein-linked inwardly rectifying potassium (GIRK) conductances and depressing calcium currents in Y 2 -expressing neurons (Acuna-Goycolea et al., 2005; Ghamari-Langroudi et al., 2005) . As Y 2 is expressed presynaptically on primary afferent neurons, we hypothesized that selective activation of Y 2 could have a dampening effect on itch transmission. In the present analysis we used a pharmacological and bioinformatical approach to address the role of Y 2 in itch.
Materials and Methods
Animals. Animal procedures were approved by the local ethical committee in Uppsala (Uppsala djurförsöksetiska nämnd) and followed the Directive 2010/63/EU of the European Parliament and of the Council, The Swedish Animal Welfare Act (Djurskyddslagen: SFS 1988:534), The Swedish Animal Welfare Ordinance (Djurskyddsförordningen: SFS 1988:539) , and the provisions regarding the use of animals for scientific purposes: DFS 2004:15 and SJVFS 2012:26. All behavioral analyses were performed in a controlled environment at 20-24°C , 45%-65% humidity, and during the light 12-hour day/night cycle. Itch Behavior, Generally. Adult male C57BL6 mice (.7 weeks old) were placed and acclimated for 5-10 minutes in a transparent plastic chamber (820 cm 3 ) with bedding before they were sedated using isoflurane and injected intrathecally with Y 2 -related substances. The chemical-induced itch behavior (described below) was recorded for 60 minutes with a digital camera, and mechanical itch (described below) was also recorded using a video camera while the experimenter stimulated the mice mechanically using 0.07-gf (gram force) von Frey filaments. One scratch episode was defined as lifting up either hind paw followed by scratching toward the pruritogen-injected or mechanically stimulated area from the time point when the paw was lifted until it was placed back on the ground. Scratch episode frequency was defined as number of scratch episodes during the defined time span, scratch episode duration was defined as total time spent scratching during the defined time span, and the duration/frequency ratio provided the mean length of a scratch episode. The itch behavior was scored manually using the software AniTracker v1.0.
Chemical Itch. Adult male C57BL6 mice (.7 weeks old) were sedated using isoflurane, after which the mice were slowly injected intrathecally (L5-L6) with 5 ml of the agonist peptide YY (PYY) 3-36 2 nM (8.1 pg/ml) or 200 pM (0.81 pg/ml), selective for Y 2 (http://www. guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId5306) (Bachem, Bubendorf, Switzerland), or the Y 2 antagonist BIIE0246 ((2S)-5-(diaminomethylideneamino)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4- [1-[2-oxo-2-[4-(6-oxo-5,11-dihydrobenzo[c] [1]benzazepin-11-yl)piperazin-1-yl]ethyl]cyclopentyl]acetyl]amino]pentanamide) (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward? objectId5306) 1 mM (0.9 mg/ml; Tocris Bioscience, Bristol, UK) or saline (9 mg/ml; Apoteket, Sweden) using a 25-ml Hamilton syringe. After injection, mice were acclimated for 10 minutes in their respective home cage for recovery before administration of a 50-ml intradermal injection in the nape of the neck of: compound 48/80 (mast cell degranulator, condensation product of N-methyl p-methoxyphenethylamine with formaldehyde) (13 mM, 100 mg/50 ml; Sigma, St. Louis), histamine (18 mM, 100 mg/50 ml; Sigma), a-methyl serotonin (3.2 mM, 30 mg/50 ml; Sigma), SLIGRL (3 mM, 100 mg/50 ml; Bachem), IL-31 [12 mM, 9.5 ng/50 ml, PeproTech, Sweden (US)] or chloroquine (CQ; 10 mM, 160 mg/50 ml; Sigma) and then transferred to a transparent cage supplied with bedding. Scratching behavior was recorded for 60 minutes using a digital camera. The investigators were not present in the room during the recordings and were blinded to the intrathecal treatment given. The itch behavior was later scored manually using the software AniTracker v1.0 and the results were displayed as the mean 6 S.E.M.
To evaluate the selectivity of 200 pM PYY 3-36 for Y 2 , 1 mM (0.9 mg/ml) Y 2 -selective antagonist BIIE0246 (http://www.guidetopharmacology. org/GRAC/ObjectDisplayForward?objectId5306); Tocris Bioscience) or saline (control) was given intrathecally 10 minutes before PYY 3-36 or saline using a 25-ml Hamilton syringe.
Atopic Dermatitis-Like Itch. Adult female Nc/Nga mice (9-10 weeks; Charlies River, Japan) were shaved dorsally and 200 mg of depilatory cream (Veet hair removal cream, Apotea, Sweden) was applied on the shaved area and removed after 2 minutes incubation. Atopic dermatitis (AD)-like symptoms were initially induced by application of 100 mg Biostir dust mite extract (Biostir Inc., Osaka, Japan) on the dorsal skin and the back sides of the ears, after which the mice were returned to their home cage. From the second dust mite treatment onwards, the mice were subjected to the following treatment twice a week for a maximum of 5 weeks: 150 ml of 4% sodium dodecyl sulfate (dissolved in saline or phosphate-buffered saline) was applied to the hairless surface to enable the mite extract to reach stratum corneum (if hair had regrown it was removed as described above), after which the surface was dried with a hair dryer (cold mode). The animal was then returned to the home cage for 2-3 hours, after which 100 mg of Biostir AD ointment was applied to the surface. During the dust mite treatment, the mice developed atopic dermatitislike symptoms and when the severity of the symptoms reached grade 7-8, according to the grading system/photos from the supplier (Biostir), the mice were enrolled in the behavior study. Basal level of itch behavior was recorded after mimicking the intrathecal injection procedure but without performing the injection, i.e., the mice were handled under anesthesia for 4-5 minutes and then recovered for 10 minutes in home cage. On the second day, and at the same time of day as the baseline recording, mice were given an intrathecal injection of either 5 ml of saline or 2 nM PYY 3-36 under anesthesia induced by 3%-4% isoflurane. When completely recovered from sedation, the mice were transferred to a transparent cage supplied with bedding. Scratching behavior was recorded for 60 minutes using a digital camera. The itch behavior was later scored manually using the software AniTracker v1.0, and the results were displayed as the mean 6 S.E.M. Observers were blinded to the intrathecal treatment given when they performed video analyses.
Mechanical Itch. Adult male C57BL6 mice (.7 weeks) were sedated using 3%-4% isoflurane and slowly injected intrathecally Activation of NPY2R Reduces Itch 75 at ASPET Journals on January 31, 2020 jpet.aspetjournals.org (L5-L6) with 5 ml of PYY 3-36 (2 nM) or saline (9 mg/ml) using a 25-ml Hamilton syringe. Mice were then acclimated for 10 minutes in a transparent cage with bedding and recorded with a digital camera. After acclimation, 0.07-gf von Frey filaments (AgnThos, Lidingö, Sweden) were applied to the nape of the neck. A behavior response upon von Frey stimuli would consist of either a shake of the fur (recorded as one shake episode) or a scratch by either hind paw (recorded as a scratch episode). Each mouse was given three repeats of five consecutive mechanical stimuli at the frequency of 1/s by a 0.07-gf von Frey filament. The mechanical itch behavior was reported as the mean number of scratch/shake episodes per repeat (per five von Frey stimuli); frequency), mean time spent scratching/shaking per repeat (per five von Frey stimuli; duration), and mean length of shake or scratch episodes (duration/frequency). The results were displayed as the mean 6 S.E.M. Shaking of the fur behavior has been shown to relate well to pruritogen-induced scratching (Jinks and Carstens 2002) .
Statistical Analysis. Gaussian distribution was tested using D'Agostino and Pearson normality test (GraphPad Prism, CA). Unpaired t test (GraphPad Prism) was used for the data sets (comparison between two different treatments) that passed the normality test, and Mann-Whitney test (GraphPad Prism) was used for the other datasets. Comparison among three different treatments was performed using a one-way analysis of variance (ANOVA) with Bonferroni posttest (GraphPad Prism). As the control level of scratch behavior induced by 48/80 differed between experiments, we only compared data within each experiment. The differences observed may be related to variances between different batches of C57BL6 mice and/or batch differences in the prepared solutions of compound 48/80.
Single (Usoskin et al., 2015; Li et al., 2016; Zeisel et al., 2018) . Total reads for each cell were normalized to the median read count of all cells, and the counts were further logarithmized [single-cell analysis in Python (SCANPY), log1p] (Wolf et al., 2018) . Top 5000 highly variable genes (HVG) were detected for all datasets (SCANPY, filter_gene_dispersion) (Zheng et al., 2017) , and the shared genes were used to transform and merge the datasets scaled to unit variance and zero mean (SCANPY, scale) using mutual nearest neighbor transformation (SCANPY, mnn_correct) (Haghverdi et al., 2018) . Both the Häring and Zeisel datasets had annotated cell types, which have been summarized by Gatto et al. (2019) , and the cell types in these two datasets were mapped according to the functional subtypes of Gatto. A linear support vector classification algorithm (scikit-learn, LinearSVC) (Pedregosa et al., 2011) was trained to predict Gatto cell types using Usoskin and Zeisel gene expression as predictor variables and Gatto cell types as target labels. Cell-type labels were thereafter predicted for Li cells. Cell-type labels were then mapped back to a merged and unscaled dataset containing all genes for expression analysis. A dotplot was constructed grouped by the Gatto cell types (SCANPY, dotplot).
Differentially expressed genes were calculated for the Itch Nppb population against the remaining cells of the dataset, with overestimated variance t test as scoring values (SCANPY, rank_ge-nes_groups). Full python code can be found at https://github.com/ JonETJakobsson/Npy2r-neurons-in-DRG.
Results
The Y 2 Receptor Regulates Histaminergic and IL-31-Induced Itch. To investigate the role of the NPY/Y 2 system in chemical itch, mice were injected intrathecally with the selective Y 2 agonist PYY 3-36 (http://www.guidetopharmacology. org/GRAC/ObjectDisplayForward?objectId5306) or saline followed by an intradermal injection of a pruritogen in the nape of the neck. Intrathecal injection of PYY 3-36 (200 pM) had no effect on histamineinduced scratch episode duration or frequency (P . 0.05), whereas injection with a higher concentration of PYY 3-36 (2 nM) attenuated the duration (P , 0.05) (Fig. 1A) but not the frequency of histamine-induced scratch episodes (P . 0.05), although a trend toward fewer scratch episodes was observed (Fig. 1B) . The mean lengths of scratch episodes did not differ between PYY 3-36 (200 pM, 2 nM) and saline-treated mice (P . 0.05) (Fig. 1C) . Hence, activation of Y 2 dampens histamine-induced itch by reducing the total time spent scratching.
Compound 48/80 is a mast cell degranulator that mainly induces release of histamine, prostaglandins, cytokines, and mast cell proteases (Moon et al., 2014) , resulting in itch (Liu et al., 2016) . Intrathecal injection of PYY 3-36 (200 pM) reduced the duration of compound 48/80-induced scratch episodes (P , 0.01), whereas the frequency of scratch episodes was similar to that of saline-treated mice (P . 0.05) (Fig. 1, A and B) . However, when mice were intrathecally injected with the higher concentration of PYY 3-36 (2 nM), both the duration and the frequency of 48/80-induced scratch episodes were significantly reduced (P , 0.001, P , 0.01) (Fig. 1, A  and B ). The mean length of scratch episodes was not changed, neither in 200 pM-(P . 0.05) nor in 2 nM PYY 3-36 -treated mice (P . 0.05) compared with saline-treated mice (Fig. 1C) , showing that Y 2 activation regulates 48/80-induced scratching behavior by reducing both the number of scratch episodes (the perception/ initiation of itch) and the total time spent scratching.
To verify the specificity of the Y 2 agonist PYY 3-36 and its effect on histaminergic itch, the selective Y 2 antagonist BIIE0246 (1 mM) (http://www.guidetopharmacology.org/GRAC/ ObjectDisplayForward?objectId5306) was intrathecally injected 10 minutes before injection of PYY 3-36 (200 pM). Both the duration and the frequency were reversed to a level similar to that of saline-treated mice upon intradermal injection of compound 48/ 80 (P 5 0.77, P 5 0.16), verifying the selectivity of PYY 3-36 for the Y 2 receptor (Fig. 2) . When only BIIE0246 was intrathecally injected prior to compound 48/80 administration, the mean length of scratch episodes (duration/frequency) was significantly increased compared with saline-treated mice (P 5 0.0015), showing that the Y 2 antagonist BIIE0246 increased the scratch response, most probably by blocking the binding of endogenous NPY (Fig. 2C) .
To evaluate if the NPY/Y 2 system also regulates nonhistaminergic scratch behavior, each of the nonhistaminergic pruritogens, a-methyl-serotonin (5HT; 30 mg), proteaseactivated receptor-2-activating peptide (SLIGRL; 100 mg), and the antimalarial drug chloroquine (160 mg), were injected intradermally after an intrathecal injection of PYY 3-36 (2 nM) or saline. There was no difference in scratch episode duration (P . 0.05, P 5 0.71, P 5 0.26) (Fig. 3A) , number of scratch episodes (P . 0.05, P 5 0.26, P 5 0.32) ( Fig. 3B ), or the mean length of scratch episodes (P . 0.05, P 5 0.71, P 5 0.26) Interleukin (IL)-31 has been implicated in the pathophysiology of atopic dermatitis (Dillon et al., 2004; Nobbe et al., 2012; Kato et al., 2014) , and to test the role of the NPY/Y 2 system in the regulation of IL-31-associated itch, mice were given an intradermal injection of IL-31 (12 mM) 10 minutes after an intrathecal injection of PYY 3-36 (2 nM) or saline. Compared with saline-treated mice, both scratch duration and mean length of scratch episodes were decreased in mice pretreated with PYY 3-36 (P 5 0.0279 and P 5 0.0035, respectively), whereas scratch episode frequency was unaltered ( Fig. 4) , showing that Y 2 regulates IL-31-induced itch by reducing the total time spent scratching and by shortening the length of the scratch episodes.
To evaluate the involvement of the NPY/Y 2 system in more persistent forms of itch, a translational model for atopic dermatitis was established using the Nc/Nga strain. Intrathecal injection of vehicle did not affect scratch episode duration (P 5 0.61), number of scratch episodes (P 5 0.93), or mean length of scratch episodes (P 5 0.22), compared with the scratch behavior prior to the injection (Fig. 4) . Likewise, intrathecal injection of the Y 2 receptor agonist PYY 3-36 (2 nM) did not affect scratch episode duration (P 5 0.14), number of scratch episodes (P 5 0.33), mean length of scratch episodes (P 5 0.07) (Fig. 4) , compared with the scratch behavior prior to the injection, although a trend toward decreased scratch behavior was observed. Thus, although the NPY/Y 2 system can reduce scratching induced by IL-31, an interleukin involved in atopic dermatitis, the NPY/Y 2 system did not have a clear effect in reducing scratch behavior in a translational model of atopy. Atopic dermatitis is also associated with IL-4, IL-5, and IL-13 (Oetjen and Kim, 2018) , which may be reflected in the different treatment outcomes.
The Y 2 Receptor Does Not Regulate Acute Mechanical Itch Behavior. To investigate the role of Y 2 in mechanical itch, mice were given an intrathecal injection of PYY 3-36 (2 nM) or saline, and their acute behavioral response following application of a 0.07 gf von Frey filament to the nape of the neck was monitored. There was no difference in shake duration (P 5 1.0) (Fig. 5A) , shake frequency (P 5 0.88) (Fig. 5B) , or mean length of shake episode (P 5 0.67) (Fig. 5C ) between PYY 3-36 -and salineinjected mice, showing that NPY/Y 2 is not involved in acute mechanical itch transmission. Scratch episode duration, frequency, and mean length of scratch episode were also monitored, but few scratch responses were observed and no differences were observed between the treatments (Supplemental Fig. 1) .
Npy2r Primary Afferent Neurons Coexpress
Itch-Associated Genes. To relate the observed itch phenotype to gene expression patterns among Npy2r-expressing DRG neurons, the DRG single-cell gene expression datasets from Usoskin et al. (2015) , Zeisel et al. (2018) , and Li et al. (2016) were merged and aligned (Fig. 6A ), resulting in a combined set of 2406 DRG neurons (622 from Usoskin, 1580 from Zeisel, and 204 from Li) . The hypothesized cell function labels assigned by Gatto were mapped to Usoskin and Zeisel cells. Cell-type labels for neurons in the Li dataset were predicted and assigned Gatto cell-type labels (Fig. 6B ). All cell types had cells from each dataset, with the exception of Cool cells, which were almost exclusively from Zeisel dataset (Fig. 6C) . Ninety percent of all Itch Nppb neurons, 38% of all Adnociceptors, and 17% of all C-nociceptors expressed Npy2r (Fig. 6D) . The other cell types had less than 10% expression of Npy2r. As the Itch Nppb population had by far the highest Npy2r expression, further analysis was focused on this population.
The top differentially expressed genes for the Itch Nppb population were found to include several itch-related genes, such as the neuropeptides Nppb and somatostatin (Sst), the interleukin 31 receptors Il31ra and Osmr, the leukotriene receptor Cystrl2, the serotonin receptor Htr1f, and the NPY receptor Npy2r (Dillon et al., 2004; Angelova-Fischer and Tsankov 2005; Nobbe et al., 2012; Mishra and Hoon, 2013; Stantcheva et al., 2016) (Fig. 6D; Table 1 ). Furthermore, the Itch Nppb population showed expression of other genes related to itch transmission, such as those involved in histaminergic signaling [histamine receptor (Hrh1) (low), phospholipase C beta 3 (Plcb3), transient receptor potential cation channel subfamily V member 1 (Trpv1)] and the SLIGR/SLIGRL receptor PAR2 (F2rl1) (low) (Nystedt et al., 1995; Shimada et al., 2006; Liu et al., 2011) . Receptors not present or absent in the Itch Nppb population were serotonin receptors (Htr2a and Htr7), histamine receptors (Hrh3 and Hrh4), BAM8-22/ SLIGRL receptor [Mrgprx1 (also known as Mrgprc11)] Liu et al., 2011) , and the chloroquine receptor Mrgpra3 (Fig. 6D) . Thus, the Itch Nppb population of primary afferents displayed enriched expression of several genes involved in pruriceptive transmission, including transducers for histaminergic and IL-31-mediated itch.
Discussion
The results presented here show that the Y 2 receptor is expressed in Itch Nppb primary afferent neurons and that jpet.aspetjournals.org activation of this inhibitory G protein-coupled receptor reduces histamine-, 48/80-, and IL-31-induced itch, whereas the scratch behavioral responses induced by the other tested nonhistaminergic pruritogens or mechanical stimuli were unaffected by the NPY/Y 2 system. Y2-Primary Afferent Neurons Are Implicated in the Sensations of Touch, Pin-Prick Pain, and Itch. In previous studies, Npy2r primary afferents were shown to mediate the sensation of pinprick pain (Arcourt et al., 2017) and be related to low threshold mechanical responsiveness (Li et al., 2011) . Arcourt and coworkers (2017) used optogenetics to activate Npy2r-Cre-expressing neurons in the dorsal root ganglia, using a bacterial artificial chromosome (BAC) transgene, which resulted in a nocifensive behavior that they related to the selective activation of Npy2r nociceptors that showed partial coexpression of (TrkA) and calcitonin gene-related peptide (CGRP) and formed free nerve endings in the skin. Li and coworkers (2011) , on the other hand, used a Npy2r-GFP mouse line and reported that Npy2r-GFP primary afferents are Ab RA-low-threshold mechanoreceptors (LTMR) that form longitudinal lanceolate endings associated with hair follicles. Thus, previous analyses were inconclusive regarding the role of Y 2 primary afferents in somatosensation.
Our analysis of 2406 primary afferent neurons, from three different scRNA-seq datasets (Usoskin et al., 2015; Li et al., 2016; Zeisel et al., 2018) , showed that Npy2r mRNA is expressed in just 8% (11/139) of Ab-LTMR, 10% (8/82) of Ad-LTMR, and 2% (9/526) of C-LTMR and that most Npy2rexpressing cells could be found in the itch-associated class (Itch Nppb 45% (148/331) and pain-associated classes C-nociceptor 22% (72/331) and Ad-nociceptor 15% (50/331) according to the Gatto nomenclature ( Fig. 6D) . Moreover, an analysis describing the role of the Runx1 transcription factor in itch-related primary afferents showed that the dorsal root ganglia of Runx1;Wnt1-Cre conditional knockout mice were completely ablated of Npy2r mRNA and various itch-associated receptors and transducers, including Nppb, Il31ra, Osmr, and Mrgpra3, and consequently displayed diminished responses to most pruritogens tested, including 48/80, a-methyl-5HT, IL-31, and chloroquine (Qi et al., 2017) , indicating a role for the NPY/Y 2 system in pruritogenic processes. Indeed, our analyses showed that activation of the inhibitory receptor Y 2 dampens histamine-, 48/80-, or IL-31-induced itch. Additionally, Itch Nppb neurons express genes associated with histamine signaling (Hrh1, Trpv1, Plcb3) and IL-31 signaling (Il31ra, Osmr), and low/absent levels of mRNA for the chloroquine receptor MrgprA3 or the main SLIGRL receptor MrgprX1 (MrgprC11), showing that NPY and Y 2 are indeed involved in specific regulation of histaminergic and IL-31-evoked itch. Thus far, Y 2 has been associated with Ab rapidly adapting (RA)-LTMR with respect to touch [(Li et al., 2011) transgenic line], pin-prick pain [(Arcourt et al., 2017) transgenic line], and itch [(Qi et al., 2017) as well as the pharmacological experiments reported here, transgenic line]. Future analysis, using transgenic tools that enable selective targeting of the different subclasses of Npy2r mRNA-expressing primary afferent neurons (Itch Nppb, C/Ad-nociceptors, and Ab/ Ad/C-LTMR, respectively), would enable us to link each population to a specific sensory role.
A potential caveat when using pharmacological tools is their limited anatomic specificity. Because low expression of Npy2r also can be detected in 5.5% of spinal dorsal horn neurons, with 77.6% of these belonging to inhibitory and 22.4% to excitatory subpopulations (Häring et al., 2018) , we cannot rule out that Y 2 could have functions in the modulation of pruriceptive signaling also within the spinal cord. However, the expression level of Npy2r is limited and the overlap (Mishra and Hoon 2013; Häring et al., 2018) . Also, dorsal rhizotomy completely abolishes Y 2 immunoreactivity in the spinal cord (Brumovsky et al., 2005) , suggesting that Y 2 is predominately located to the central terminals of primary afferents projecting to the spinal cord and that NPY/Y 2 inhibits itch mainly through the interaction with itchassociated primary afferents. Itch Nppb Primary Afferents Coexpress Somatostatin and Nppb. The neuropeptides Nppb and Sst are highly coexpressed in the Itch Nppb population (Gatto et al., 2019) (Fig. 6D ). Nppb is a well established mediator of itch (Mishra and Hoon, 2013; Pitake et al., 2018) , and activation of Sst primary afferents induces scratching (Huang et al., 2018) , whereas ablation of primary afferent Sst neurons decreases scratching induced by IL-31, histamine, chloroquine, and LY344864 (a 5HT 1F agonist) (Stantcheva et al., 2016) , arguing that Npy2r/Nppb/Sst -rich primary afferents mediate itch (Fig. 6E) .
Five somatostatin receptor subtypes are found in mammals, and they have similar signaling pathways (http://www. guidetopharmacology.org/GRAC/FamilyDisplayForward? familyId561). Among these, the Sst2a receptor is almost exclusively expressed by inhibitory neurons in the spinal cord (Häring et al., 2018) . This ligand-receptor interaction leads to neuronal hyperpolarization , and targeting Sst2a with a specific agonist increases, whereas a specific antagonist decreases, histamine-, Nppb-, and Grpinduced scratching, suggesting a disinhibition mechanism (Huang et al., 2018) . As Sst, Nppb, and Npy2r display extensive overlap in primary afferent neurons, this suggests that the Itch Nppb neurons may promote scratching both by driving itch circuits via excitation and disinhibition (Fig. 6E) .
Spinal NPY Interneurons Can Dampen Itch in Several Possible Ways. Spinal NPY interneurons are activated by noxious mechanical, chemical, temperature, and touch stimuli (Liu et al., 2010; Polgar et al., 2013; Bourane et al., 2015) and hence could represent neuronal population-enabling counter-stimuli, for instance, scratch or noxious heat, to inhibit itch (Fig. 6E ). Ablation of spinal NPY neurons results in alloknesis to mechanical stimuli and spontaneous scratching, indicating that NPY neurons indeed gate/inhibit itch (Bourane et al., 2015) . We have recently shown that selective activation of spinal Y 1 -expressing neurons reduces the duration and frequency of mechanically induced scratching and the duration of histamine-or 48/80-induced scratching, resulting in shorter scratch episodes (Gao et al., 2018) . The Y 1 receptor is mainly expressed by excitatory interneurons (Häring et al., 2018) , showing partly overlapping Sst expression (Zhang et al., 1999) . Sst in turn inhibits inhibitory (disinhibition) class B basic helix-loop-helix protein 5 (Bhlhb5) neurons implicated in the regulation of itch (Ross et al., 2010; Kardon et al., 2014) (Fig. 6E ). Hence, our present data indicate that NPY can reduce itch (scratching behavior) both through Y 1 -mediated inhibition of spinal circuits, which reduces the length of the episodes of scratching (counter-stimuli) (Gao et al., 2018) , and through Y 2 -mediated inhibition of itchtransmitting primary afferents, which results in a reduction of both the initiation of scratching/perception of itch (fewer scratch episodes) and the duration of the behavior (Fig. 6E ). The NPY/Y 1 /Y 2 system thus constitutes an elaborate circuit that controls itch transmission both by reducing the perceived itch and by making the counter-stimuli (scratch) more efficient in relieving itch.
